Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Prostate Cancer

  Free Subscription


22.01.2018

1 AJR Am J Roentgenol
1 Am J Pathol
3 BMC Cancer
2 Cancer
3 Cancer Lett
1 Eur Urol
1 Int J Cancer
1 Int J Radiat Oncol Biol Phys
3 Int J Urol
1 J Magn Reson Imaging
2 J Urol
2 Lancet Oncol
1 Nat Rev Urol
1 PLoS One
4 Prostate
1 Ther Adv Urol
1 Urol Int


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJR Am J Roentgenol

  1. METSER U, Berlin A, Halankar J, Murphy G, et al
    (18)F-Fluorocholine PET Whole-Body MRI in the Staging of High-Risk Prostate Cancer.
    AJR Am J Roentgenol. 2018 Jan 11:1-6. doi: 10.2214/AJR.17.18567.
    PubMed     Text format     Abstract available


    Am J Pathol

  2. GONNISSEN A, Isebaert S, Perneel C, McKee CM, et al
    Patched 1 Expression Correlates with Biochemical Relapse in High-Risk Prostate Cancer Patients.
    Am J Pathol. 2018 Jan 12. pii: S0002-9440(17)30378.
    PubMed     Text format     Abstract available


    BMC Cancer

  3. SANGHERA S, Coast J, Martin RM, Donovan JL, et al
    Cost-effectiveness of prostate cancer screening: a systematic review of decision-analytical models.
    BMC Cancer. 2018;18:84.
    PubMed     Text format     Abstract available

  4. GUERTIN MH, Robitaille K, Pelletier JF, Duchesne T, et al
    Effects of concentrated long-chain omega-3 polyunsaturated fatty acid supplementation before radical prostatectomy on prostate cancer proliferation, inflammation, and quality of life: study protocol for a phase IIb, randomized, double-blind, placebo-c
    BMC Cancer. 2018;18:64.
    PubMed     Text format     Abstract available

  5. CHEN CB, Eskin M, Eurich DT, Majumdar SR, et al
    Metformin, Asian ethnicity and risk of prostate cancer in type 2 diabetes: a systematic review and meta-analysis.
    BMC Cancer. 2018;18:65.
    PubMed     Text format     Abstract available


    Cancer

  6. MCDUFF SGR, Chen MH, Renshaw AA, Loffredo MJ, et al
    Impact of time to testosterone rebound and comorbidity on the risk of cause-specific mortality in men with unfavorable-risk prostate cancer.
    Cancer. 2018 Jan 16. doi: 10.1002/cncr.31217.
    PubMed     Text format     Abstract available

  7. MCHUGH DJ, Root JC, Nelson CJ, Morris MJ, et al
    Androgen-deprivation therapy, dementia, and cognitive dysfunction in men with prostate cancer: How much smoke and how much fire?
    Cancer. 2018 Jan 16. doi: 10.1002/cncr.31153.
    PubMed     Text format     Abstract available


    Cancer Lett

  8. MENG X, Vander Ark A, Daft P, Woodford E, et al
    Loss of TGF-beta signaling in osteoblasts increases basic-FGF and promotes prostate cancer bone metastasis.
    Cancer Lett. 2018 Jan 11. pii: S0304-3835(18)30040.
    PubMed     Text format     Abstract available

  9. LI X, Li J, Cai Y, Peng S, et al
    Hyperglycaemia-induced miR-301a promotes cell proliferation by repressing p21 and Smad4 in prostate cancer.
    Cancer Lett. 2018 Jan 10. pii: S0304-3835(18)30053.
    PubMed     Text format     Abstract available

  10. MITOBE Y, Takayama KI, Horie-Inoue K, Inoue S, et al
    Prostate cancer-associated lncRNAs.
    Cancer Lett. 2018 Jan 9. pii: S0304-3835(18)30034.
    PubMed     Text format     Abstract available


    Eur Urol

  11. STROM P, Nordstrom T, Gronberg H, Eklund M, et al
    The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential.
    Eur Urol. 2018 Jan 10. pii: S0302-2838(17)31096.
    PubMed     Text format     Abstract available


    Int J Cancer

  12. ARTHUR R, Williams R, Garmo H, Holmberg L, et al
    Serum inflammatory markers in relation to prostate cancer severity and death in the Swedish AMORIS study.
    Int J Cancer. 2018 Jan 11. doi: 10.1002/ijc.31256.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  13. PISANSKY TM, Tendulkar RD
    In Reply to Ghadjar et al.
    Int J Radiat Oncol Biol Phys. 2017;97:439-440.
    PubMed     Text format    


    Int J Urol

  14. SAKAMOTO S
    Editorial Comment to Cell death under epithelial-mesenchymal transition control in prostate cancer therapeutic response.
    Int J Urol. 2018 Jan 17. doi: 10.1111/iju.13510.
    PubMed     Text format    

  15. TAKEI A, Sakamoto S, Wakai K, Tamura T, et al
    Duration of androgen deprivation therapy and nadir of testosterone at 20 ng/dL predict testosterone recovery to supracastrate level in prostate cancer patients who received external beam radiotherapy.
    Int J Urol. 2018 Jan 11. doi: 10.1111/iju.13521.
    PubMed     Text format     Abstract available

  16. BEGEMANN D, Anastos H, Kyprianou N
    Cell death under epithelial-mesenchymal transition control in prostate cancer therapeutic response.
    Int J Urol. 2018 Jan 17. doi: 10.1111/iju.13505.
    PubMed     Text format     Abstract available


    J Magn Reson Imaging

  17. GINSBURG SB, Taimen P, Merisaari H, Vainio P, et al
    Patient-specific pharmacokinetic parameter estimation on dynamic contrast-enhanced MRI of prostate: Preliminary evaluation of a novel AIF-free estimation method.
    J Magn Reson Imaging. 2016 Jun 10. doi: 10.1002/jmri.25330.
    PubMed     Text format     Abstract available


    J Urol

  18. CHALFIN HJ, Glavaris SA, Malihi PD, Sperger JM, et al
    Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Localized Patients Undergoing Radical Prostatectomy Across Multiple Rare Cell Detection Platforms.
    J Urol. 2018 Jan 12. pii: S0022-5347(18)30065-X. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available

  19. SANDA MG, Cadeddu JA, Kirkby E, Chen RC, et al
    Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options.
    J Urol. 2018 Jan 10. pii: S0022-5347(18)30014-4. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


    Lancet Oncol

  20. PENSON DF
    Considering quantity and quality of life in metastatic castration-naive prostate cancer.
    Lancet Oncol. 2018 Jan 8. pii: S1470-2045(17)30908.
    PubMed     Text format    

  21. CHI KN, Protheroe A, Rodriguez-Antolin A, Facchini G, et al
    Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
    Lancet Oncol. 2018 Jan 8. pii: S1470-2045(17)30911.
    PubMed     Text format     Abstract available


    Nat Rev Urol

  22. FREEDLAND S
    Prostate cancer: Race and prostate cancer personalized medicine: the future.
    Nat Rev Urol. 2018 Jan 16. pii: nrurol.2017.215. doi: 10.1038/nrurol.2017.
    PubMed     Text format    


    PLoS One

  23. BARAKAT DJ, Suresh R, Barberi T, Pienta KJ, et al
    Absence of myeloid Klf4 reduces prostate cancer growth with pro-atherosclerotic activation of tumor myeloid cells and infiltration of CD8 T cells.
    PLoS One. 2018;13:e0191188.
    PubMed     Text format     Abstract available


    Prostate

  24. XU L, Shen M, Chen X, Zhu R, et al
    Adipocytes affect castration-resistant prostate cancer cells to develop the resistance to cytotoxic action of NK cells with alterations of PD-L1/NKG2D ligand levels in tumor cells.
    Prostate. 2018 Jan 12. doi: 10.1002/pros.23479.
    PubMed     Text format     Abstract available

  25. HENDRIKS RJ, Dijkstra S, Smit FP, Vandersmissen J, et al
    Epigenetic markers in circulating cell-free DNA as prognostic markers for survival of castration-resistant prostate cancer patients.
    Prostate. 2018 Jan 12. doi: 10.1002/pros.23477.
    PubMed     Text format     Abstract available

  26. KIMBROUGH-ALLAH MN, Millena AC, Khan SA
    Differential role of PTEN in transforming growth factor beta (TGF-beta) effects on proliferation and migration in prostate cancer cells.
    Prostate. 2018 Jan 16. doi: 10.1002/pros.23482.
    PubMed     Text format     Abstract available

  27. SU Z, Zhang M, Xu M, Li X, et al
    MicroRNA181c inhibits prostate cancer cell growth and invasion by targeting multiple ERK signaling pathway components.
    Prostate. 2018 Jan 16. doi: 10.1002/pros.23478.
    PubMed     Text format     Abstract available


    Ther Adv Urol

  28. PATEL MP, Schulman A, Shah KP, Anderson JB, et al
    Engaging the primary care community to encourage appropriate prostate cancer screening.
    Ther Adv Urol. 2017;10:11-16.
    PubMed     Text format     Abstract available


    Urol Int

  29. BORKOWETZ A, Renner T, Platzek I, Toma M, et al
    Evaluation of Magnetic Resonance Imaging/Ultrasound-Fusion Biopsy in Patients with Low-Risk Prostate Cancer Under Active Surveillance Undergoing Surveillance Biopsy.
    Urol Int. 2018 Jan 16. pii: 000486041. doi: 10.1159/000486041.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: